Abacavir Lamivudin Sandoz Compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abacavir lamivudin sandoz compresse rivestite con film

sandoz pharmaceuticals ag - abacavirum, lamivudinum - compresse rivestite con film - abacavirum 600 mg ut abacaviri hydrochloridum monohydricum, lamivudinum 300 mg, cellulosum microcristallinum, crospovidonum, povidonum k 30, magnesii stearas, e 172 (flavum), Überzug: hypromellosum, macrogolum 400, polysorbatum 80, e 110 1.415 mg, e 171, pro compresso obducto. - le infezioni da hiv - synthetika

Triumeq Unione Europea - italiano - EMA (European Medicines Agency)

triumeq

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - infezioni da hiv - antivirali per uso sistemico - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

Abacavir-Lamivudin-Mepha 600 mg/300 mg Compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abacavir-lamivudin-mepha 600 mg/300 mg compresse rivestite con film

mepha pharma ag - abacavirum, lamivudinum - compresse rivestite con film - abacavirum 600 mg, lamivudinum 300 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carboxymethylamylum natricum a, magnesii stearas, Überzug: hypromellosum, macrogolum 4000, polysorbatum 80, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 3.276 mg. - l'infezione da hiv - synthetika

TENOFOVIR DISOPROXIL TEVA Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

tenofovir disoproxil teva

teva italia s.r.l. - tenofovir disoproxil - tenofovir disoproxil

METADONE CLORIDRATO MOLTENI Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

metadone cloridrato molteni

l. molteni & c. dei f.lli alitti societa' di esercizio s.p.a. - metadone - metadone

Adempas Unione Europea - italiano - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - ipertensione, polmonare - antipertensivi per l'ipertensione arteriosa polmonare - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l'efficacia è stata dimostrata in un pah della popolazione eziologie di idiopatica o ereditaria ipa o pah associata a malattia del tessuto connettivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.